Zealand Pharma A/S
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Zealand Pharma A/S, a biotechnology company focused on the discovery, design, development, and commercialization of innovative peptide-based medicines addressing unmet medical needs, operates primarily in the areas of obesity, rare diseases, and chronic inflammation. Founded in 1998 and headquartered in Søborg, Denmark, with additional operations in the United States, the company offers a pipeline of investigational candidates including petrelintide, a long-acting amylin analog for weight management; dapiglutide, a long-acting GLP-1/GLP-2 receptor dual agonist targeting obesity and low-grade inflammation; survodutide, a long-acting glucagon/GLP-1 receptor dual agonist licensed to Boehringer Ingelheim for obesity and metabolic dysfunction-associated steatohepatitis; ZP6590, a GIP receptor agonist for obesity; dasiglucagon for continuous infusion in congenital hyperinsulinism and other formulations such as Zegalogue for severe hypoglycemia; glepaglutide, a long-acting GLP-2 analog for short bowel syndrome; ZP9830, a Kv1.3 ion channel blocker for T-cell-driven autoimmune diseases; and ZP10068, a complement C3 inhibitor for complement-mediated diseases. Zealand Pharma targets patients with metabolic, gastrointestinal, and inflammatory conditions globally through research, clinical development, and strategic partnerships. In recent developments, the company entered an exclusive collaboration and licensing agreement with Roche in March 2025 to co-develop and co-commercialize petrelintide as a monotherapy and in fixed-dose combination with Roche's CT-388 for obesity, providing upfront payments of USD 1.65 billion and potential total consideration up to USD 5.3 billion; closed this agreement in May 2025 with Phase 2b ZUPREME trials advancing; submitted a Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome; reported positive topline results from a 28-week Phase 1b trial of dapiglutide; completed an upsized equity offering raising approximately DKK 835 million in June 2024 to fund obesity programs; and appointed Steven Johnson as Chief Development Officer to strengthen leadership in obesity innovation.
Zealand Pharma to participate in the Goldman Sachs Global Healthcare Conference
Zealand Pharma - Transactions related to share buy-back program (week 22, 2026)
Zealand Pharma - Transactions related to share buy-back program (week 22, 2026)
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Zealand Pharma to participate in the Jefferies Global Healthcare Conference
Zealand Pharma to Present Data at the American Diabetes Association's 2026 Scientific Sessions
Zealand Pharma to Present Data at the American Diabetes Association's 2026 Scientific Sessions
Zealand Pharma - Transactions related to share buy-back program (week 21, 2026)
Zealand Pharma - Transactions related to share buy-back program (week 21, 2026)
Resolutions from Zealand Pharma's Extraordinary General Meeting 2026
Zealand Pharma - Transactions related to share buy-back program (weeks 19-20, 2026)
Zealand Pharma - Execution framework for share buy-back program
Zealand Pharma Announces Financial Results for the First Three Months of 2026
Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program
The Zealand Pharma Board of Directors proposes to elect Camilla Sylvest to the Board of Directors at an upcoming Extraordinary General Meeting
Zealand Pharma convenes Extraordinary General Meeting on May 26, 2026
Zealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial results
Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management
Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management